206 related articles for article (PubMed ID: 34765739)
1. Diverse roles of bitter melon (
Sur S; Ray RB
J Cancer Metastasis Treat; 2021; 7():. PubMed ID: 34765739
[TBL] [Abstract][Full Text] [Related]
2. Bitter Melon (
Sur S; Ray RB
Cancers (Basel); 2020 Jul; 12(8):. PubMed ID: 32726914
[TBL] [Abstract][Full Text] [Related]
3. Bitter melon derived extracellular vesicles enhance the therapeutic effects and reduce the drug resistance of 5-fluorouracil on oral squamous cell carcinoma.
Yang M; Luo Q; Chen X; Chen F
J Nanobiotechnology; 2021 Aug; 19(1):259. PubMed ID: 34454534
[TBL] [Abstract][Full Text] [Related]
4. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
Raina K; Kumar D; Agarwal R
Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
[TBL] [Abstract][Full Text] [Related]
5.
Bortolotti M; Mercatelli D; Polito L
Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
[No Abstract] [Full Text] [Related]
6. Bitter melon: a panacea for inflammation and cancer.
Dandawate PR; Subramaniam D; Padhye SB; Anant S
Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
[TBL] [Abstract][Full Text] [Related]
7. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
[TBL] [Abstract][Full Text] [Related]
8. Effects of dietary wild bitter melon (Momordica charantia var. abbreviate Ser.) extract on glucose and lipid metabolism in HFD/STZ-induced type 2 diabetic rats.
Sun K; Ding M; Fu C; Li P; Li T; Fang L; Xu J; Zhao Y
J Ethnopharmacol; 2023 Apr; 306():116154. PubMed ID: 36634725
[TBL] [Abstract][Full Text] [Related]
9. Emerging Antitumor Activities of the Bitter Melon (Momordica charantia).
Fang EF; Froetscher L; Scheibye-Knudsen M; Bohr VA; Wong JH; Ng TB
Curr Protein Pept Sci; 2019; 20(3):296-301. PubMed ID: 29932035
[TBL] [Abstract][Full Text] [Related]
10. Quantitative determination of cucurbitane-type triterpenes and triterpene glycosides in dietary supplements containing bitter melon (Momordica charantia) by HPLC-MS/MS.
Ma J; Krynitsky AJ; Grundel E; Rader JI
J AOAC Int; 2012; 95(6):1597-608. PubMed ID: 23451374
[TBL] [Abstract][Full Text] [Related]
11. Thermal treatment enhances the α-glucosidase inhibitory activity of bitter melon (Momordica charantia) by increasing the free form of phenolic compounds and the contents of Maillard reaction products.
Hsieh HJ; Lin JA; Chen KT; Cheng KC; Hsieh CW
J Food Sci; 2021 Jul; 86(7):3109-3121. PubMed ID: 34146408
[TBL] [Abstract][Full Text] [Related]
12. Hypoglycemic efficacy and safety of Momordica charantia (bitter melon) in patients with type 2 diabetes mellitus.
Kim SK; Jung J; Jung JH; Yoon N; Kang SS; Roh GS; Hahm JR
Complement Ther Med; 2020 Aug; 52():102524. PubMed ID: 32951763
[TBL] [Abstract][Full Text] [Related]
13. Bitter melon: antagonist to cancer.
Nerurkar P; Ray RB
Pharm Res; 2010 Jun; 27(6):1049-53. PubMed ID: 20198408
[TBL] [Abstract][Full Text] [Related]
14. Antioxidant properties and quantitative UPLC-MS analysis of phenolic compounds from extracts of fenugreek (Trigonella foenum-graecum) seeds and bitter melon (Momordica charantia) fruit.
Kenny O; Smyth TJ; Hewage CM; Brunton NP
Food Chem; 2013 Dec; 141(4):4295-302. PubMed ID: 23993618
[TBL] [Abstract][Full Text] [Related]
15. Dangerous interaction of bitter melon (
Unsal O; Sütcüoğlu O; Yazıcı O
J Oncol Pharm Pract; 2022 Mar; 28(2):486-488. PubMed ID: 34569860
[TBL] [Abstract][Full Text] [Related]
16. Strategies to improve palatability and increase consumption intentions for Momordica charantia (bitter melon): a vegetable commonly used for diabetes management.
Snee LS; Nerurkar VR; Dooley DA; Efird JT; Shovic AC; Nerurkar PV
Nutr J; 2011 Jul; 10():78. PubMed ID: 21794176
[TBL] [Abstract][Full Text] [Related]
17. Comparative Pre-clinical Efficacy of Chinese and Indian Cultivars of Bitter Melon (
Kandhari K; Paudel S; Raina K; Agarwal C; Kant R; Wempe MF; O'Bryant C; Agarwal R
J Cancer Prev; 2021 Dec; 26(4):266-276. PubMed ID: 35047453
[TBL] [Abstract][Full Text] [Related]
18. Identification and Characterization of Phenylpropanoid Biosynthetic Genes and Their Accumulation in Bitter Melon (Momordica charantia).
Cuong DM; Kwon SJ; Jeon J; Park YJ; Park JS; Park SU
Molecules; 2018 Feb; 23(2):. PubMed ID: 29466305
[TBL] [Abstract][Full Text] [Related]
19. Bitter melon (Momordica charantia): a review of efficacy and safety.
Basch E; Gabardi S; Ulbricht C
Am J Health Syst Pharm; 2003 Feb; 60(4):356-9. PubMed ID: 12625217
[TBL] [Abstract][Full Text] [Related]
20. Metabolite profiling and in vitro biological activities of two commercial bitter melon (Momordica charantia Linn.) cultivars.
Perez JL; Jayaprakasha GK; Patil BS
Food Chem; 2019 Aug; 288():178-186. PubMed ID: 30902279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
